Victory Capital Management
CNCE

Victory Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Victory Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-8,930
Closed -$78K – 3509
2020
Q1 		$78K Buy
+8,930
New +$88.1K ﹤0.01% 2613
2019
Q4 		– Sell
-3,985
Closed -$23K – 3494
2019
Q3 		$23K Buy
+3,985
New +$42.3K ﹤0.01% 3005

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LC
L1 Capital Melbourne VIC 3000, Australia $2.55B AUM 80.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Victory Capital Management's CNCE Position: Q2 2020 in Review

Victory Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2020, closing a stake of 8,930 shares — an estimated $78K sold.

Victory Capital Management first reported a position in CNCE in Q3 2019 and held it in 2 quarters. The position peaked at $78K in Q1 2020. 91 funds tracked by Wall St. Rank hold CNCE as of Q2 2020.

  • Victory Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 8,930 Concert Pharmaceuticals, Inc. shares in Q2 2020, an estimated $78K.
  • Victory Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Concert Pharmaceuticals, Inc. position peaked at $78K in Q1 2020.
  • 91 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.